AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...
GlobalData on MSN23h
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nodBefore the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...
MedPage Today on MSN2d
FDA OKs New Option for Rare Immune-Mediated VasculitisEGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
Findings showed a statistically significant and clinically meaningful reduction in the annualized rate of moderate to severe exacerbations with mepolizumab vs placebo. Mepolizumab was found to ...
The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...
The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.
In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.
AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback